采用同步整合生物学等效剂量递增的肺部立体定向体部放射治疗用于周围型非小细胞肺癌。
Lung stereotactic body radiation therapy using simultaneous integrated BED-escalation for peripherally located non-small cell lung cancer.
作者信息
Ladbury Colton J, Sampath Sagus
机构信息
Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA, USA.
出版信息
J Radiosurg SBRT. 2022;8(3):181-187.
PURPOSE
Report the outcomes of patients with non-small cell lung cancer (NSCLC) and peripheral tumors treated with simultaneous integrated biologically equivalent dose (BED)-escalation (SIBE) lung stereotactic body radiation therapy (SBRT) to achieve dose escalation.
MATERIALS/METHODS: Patients with NSCLC within 5 mm of the chest wall treated with a SIBE approach were eligible. Patients received 60 Gy in 5 fractions, with dose decreased to 50 Gy based on proximity to the chest wall. Dosimetry, oncologic outcomes, and toxicity were evaluated.
RESULTS
Twenty-four patients met inclusion criteria. Median BED to the PTV was 135.4 Gy. Median chest wall V30 was 18.7 cc. The 3-year LC, OS, and PFS of the non-metastatic cohort was 93%, 35%, and 39%, respectively. The crude rate of chest wall toxicity was 12.5%, with no rib fractures.
CONCLUSIONS
SIBE lung SBRT appears to be well tolerated and achieves favorable local control rates and survival.
目的
报告采用同步整合生物等效剂量（BED）递增（SIBE）的肺部立体定向体部放射治疗（SBRT）治疗非小细胞肺癌（NSCLC）及周围型肿瘤患者以实现剂量递增的结果。
材料/方法：符合条件的患者为采用SIBE方法治疗且肿瘤距胸壁5mm以内的NSCLC患者。患者接受5次分割的60Gy照射，根据距胸壁的距离将剂量降至50Gy。评估剂量测定、肿瘤学结果和毒性。
结果
24例患者符合纳入标准。计划靶体积（PTV）的中位BED为135.4Gy。胸壁V30的中位数为18.7cc。非转移队列的3年局部控制率（LC）、总生存期（OS）和无进展生存期（PFS）分别为93%、35%和39%。胸壁毒性的粗发生率为12.5%，无肋骨骨折。
结论
SIBE肺部SBRT似乎耐受性良好，并能实现良好的局部控制率和生存率。
Zotero 插件